Venlafaxine 50 mg Immediate Release Tablets — Generic For Effexor — Rising Pharma

Medication Summary

Medication Summary: This section summarizes DailyMed drug label information to make the label easier to understand. It is not a substitute for the official label, pharmacist counseling, prescriber instructions, or medical advice.

Overview

Venlafaxine tablets, USP are a prescription antidepressant used to treat major depressive disorder in adults. The label says the medicine was studied in short-term controlled trials and also in longer-term studies to help maintain antidepressant response in some patients.

The label warns that antidepressants can increase the risk of suicidal thinking and behavior in children, adolescents, and young adults, and that patients of all ages should be watched closely for worsening depression, suicidality, or unusual behavior changes, especially when starting treatment or changing the dose. Venlafaxine is not approved for pediatric patients.

Important safety information in the label includes the risk of serotonin syndrome, sustained increases in blood pressure, angle-closure glaucoma in people with anatomically narrow angles, and symptoms that can happen when treatment is stopped suddenly. The label also lists contraindications with MAOIs and with hypersensitivity to venlafaxine or its excipients.

Storage Information

protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] in a dry place. Dispense in a well-closed container as defined in the USP. store venlafaxine tablets ? Store venlafaxine tablets at room temperature between 20° to 25°C (68° to 77°F).

Key Counseling Points

• Take venlafaxine only as prescribed.
• This medicine is used for major depressive disorder.
• Do not use venlafaxine with MAOIs intended to treat psychiatric disorders, or within 7 days of stopping venlafaxine; venlafaxine is also contraindicated within 14 days of stopping an MAOI.
• Do not start venlafaxine if you are being treated with linezolid or intravenous methylene blue.
• Watch for worsening depression, suicidal thoughts, or unusual changes in behavior, especially when treatment starts or the dose changes.
• Tell the prescriber right away about symptoms that may suggest serotonin syndrome, such as agitation, hallucinations, rapid heartbeat, labile blood pressure, tremor, rigidity, or diarrhea.
• Regular blood pressure monitoring is recommended because venlafaxine can cause sustained increases in blood pressure.
• Do not stop venlafaxine suddenly if it can be avoided; the label says gradual dose reduction is recommended because stopping or lowering the dose can cause symptoms.
• Tell the prescriber if you have a history of bipolar disorder, because the label says patients with depressive symptoms should be screened for bipolar risk before treatment.
• The label says venlafaxine is not approved for use in pediatric patients.

Helpful Patient Education

Venlafaxine tablets, USP are a prescription antidepressant used in the treatment of major depressive disorder. DailyMed labeling includes important safety information about suicidality monitoring, serotonin syndrome, blood pressure changes, and discontinuation symptoms.

This medication information is based on the product label and is intended to help patients and caregivers understand key approved uses, warnings, and counseling points for venlafaxine tablets.

Medication Summary last generated: 2026-07-12 03:09:44